Since established in 1988, AIDS Research Center (ARC) has been
working on HIV- and other retroviruses-related diseases. The principal
objective of ARC is to contribute to the control of HIV infection.
>>To the ARC introduction movie（Mac-only）
The New York-based International AIDS Vaccine Initiative (IAVI) and the Japan-based biotech DNAVEC Corporation announced the start of a Phase I clinical trial of an HIV vaccine candidate using Sendai virus (SeV) vector at three locations including England and Rwanda.
The SeV vector AIDS vaccine system has been developed by our research group.
updated on June 4, 2016